Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
184.50
-3.50 (-1.86%)
Sep 26, 2025, 2:38 PM CST

TPE:6919 Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
286,16394,36523,5407,528--
Upgrade
Market Cap Growth
220.21%300.87%212.69%---
Upgrade
Enterprise Value
276,77184,68522,6946,297--
Upgrade
Last Close Price
184.5061.5019.136.11--
Upgrade
PS Ratio
6383.002123.71604.64587.23--
Upgrade
PB Ratio
30.459.736.296.47--
Upgrade
P/TBV Ratio
30.459.736.296.47--
Upgrade
EV/Sales Ratio
-1905.86582.91491.18--
Upgrade
Debt / Equity Ratio
0.000.000.010.030.062.81
Upgrade
Asset Turnover
0.010.010.020.010.030.05
Upgrade
Inventory Turnover
2.137.045.992.252.412.89
Upgrade
Quick Ratio
117.48183.4250.4823.0415.001.45
Upgrade
Current Ratio
118.02184.0250.8123.4115.261.72
Upgrade
Return on Equity (ROE)
-9.69%-8.76%-19.92%-31.64%-64.89%-528.22%
Upgrade
Return on Assets (ROA)
-6.44%-6.59%-12.68%-20.53%-30.68%-33.22%
Upgrade
Return on Capital (ROIC)
-6.52%-6.65%-12.96%-21.32%-33.58%-40.80%
Upgrade
Earnings Yield
-0.22%-0.62%-2.08%-3.80%--
Upgrade
FCF Yield
-0.16%-0.56%-1.84%-3.41%--
Upgrade
Buyback Yield / Dilution
-13.79%-15.40%-5.77%-27.35%-23.49%-6.52%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.